ALS Drug Development Gets FDA Hearing
PALS, caregivers, ALS advocates and researchers will gather on Monday February 25th to talk to the FDA about ALS, from the patient perspective.
Trial News & Events
Phase III Trial of Dexpramipexole (EMPOWER) Results Announced
Biogen Idec announced phase III EMPOWER trial did not reach its endpoints and did not show efficacy. NEALS Co-Chair Merit Cudkowicz reacts, "While we had all hoped for a positive result, ALS researchers remain truly committed to finding a cure for this disease."